Merck says it will continue study of Vytorin effectiveness.
The AP (3/12, Johnson) reports that "researchers will continue a study of a controversial Merck & Co. cholesterol drug," Vytorin (ezetimibe and simvastatin), "after safety monitors decided data so far indicate the drug is safe and effective, the company said Thursday." Merck "said the data safety monitoring board overseeing the study, called IMPROVE-IT, did a preplanned analysis of results halfway through the study." The research "is intended to determine whether Merck's combination cholesterol pill Vytorin prevents heart attacks, strokes, and deaths more than just one of its components, Zocor [simvastatin], which is available as a cheap generic pill." Reuters (3/12, Pierson) also covers the story.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment